The standard of care (SOC) for the treatment of HCV genotype 2 (HCV-2) was pegylated interferon alpha plus ribavirin (PEG-IFN/RBV) at weight-based doses for a response-guided duration. The launches of sofosbuvir and daclatasvir in 2014 have resulted in new, better tolerated and shorter treatment. The combination of sofosbuvir and RBV for 12 weeks appears to be the new SOC in both European and American guidelines. The cost and therefore the access to this treatment remains a problem in many countries because of major economic constraints. For the few more difficult-to-treat patients, a combination of direct acting antivirals may be suitable and is being studied in ongoing trials. Because of rapidly changing treatment recommendations, the decision to treat HCV-2 patients with currently approved drugs or to wait until a better option is available in the future, must be made according to the stage of fibrosis.
Keywords: AASLD guidelines; European Association for the Study of the Liver guidelines; MK-5172; daclatasvir; genotype 2; hepatitis C virus; ombitasvir; paritaprevir; pegylated interferon alpha; ribavirin; sofosbuvir.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.